Tasly Pharmaceutical (“Tasly”) (SHSE:600535) is a leading traditional Chinese medicine (TCM) developer and distributor with a focus on the treatment of cardiovascular and cerebrovascular diseases. Given the high potential of essential drug tendering ramp-up in most provinces in 2015 in China, Tasly will likely continue to enjoy strong sales growth going forward. The company has a strong potential for product internationalization to drive future growth. Its Compound Danshen Dripping Pills is undergoing a Phase III clinical trial in the US and could potentially become the first TCM product to enter the US market as a prescription drug.
From Value Partners (Trades, Portfolio)’ Classic Fund Q4 2014 Commentary.
